Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial
Background: Retatrutide, an agonist of glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors, is in development for the treatment of obesity. We interviewed participants exiting a phase 2 trial to understand the impact of retatrutide on eating behaviors, physi...
Uloženo v:
| Hlavní autoři: | , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier
2025-12-01
|
| Edice: | Obesity Pillars |
| Témata: | |
| On-line přístup: | http://www.sciencedirect.com/science/article/pii/S2667368125000646 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|